会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Application of puerarin in the preparation of P2X3 mediated drugs for pain/nervous system diseases
    • 应用葛根素制备P2X3介导的药物用于疼痛/神经系统疾病
    • US08362070B2
    • 2013-01-29
    • US12922245
    • 2010-06-29
    • Shangdong LiangChangshui XuYun GaoGuilin LiJiari LinShuangmei LiuHan LiuJun ZhangXin Li
    • Shangdong LiangChangshui XuYun GaoGuilin LiJiari LinShuangmei LiuHan LiuJun ZhangXin Li
    • A61K31/35A61K31/70
    • A61K31/352
    • The invention relates to the new usage of puerarin in the field of pharmaceutical products, in other words, it relates to the application of puerarin in the preparation of drugs for P2X3 mediated pain/nervous system diseases. The experiment shows that puerarin can inhibit pain-related behavioral responses, subsequently immunohistochemical analysis, in situ hybridization, RT-PCR, protein blotting and other techniques were utilized to observe the inhibition of puerarin on mRNA and protein expression of P2X3 receptor in dorsal root ganglion of rats with neuropathic pain and in dorsal root ganglion and sensory nerve ending in the burn model of rats, it was found by using whole-cell patch clamp technique that puerarin can significantly reduce the electric current activated by P2X3 receptor agonist in the neuron of dorsal root ganglion of rats with neuropathic pain. The experiment proves that the mechanism for the inhibitory effects of puerarin on acute and chronic pain is to block the transmission of pain sense information that is mediated by P2X3 receptor in primary sensory neurons. The invention provides a kind of new method for the prevention and treatment on acute and chronic pain, and it also indicates that puerarin can act as a antagonist for P2X3 receptor, which will be helpful for the application of drugs in the prevention and treatment on P2X3 receptor involved nervous system diseases.
    • 本发明涉及葛根素在药物领域的新用途,换句话说,涉及葛根素在制备P2X3介导的疼痛/神经系统疾病药物中的应用。 实验表明,葛根素可以抑制疼痛相关的行为反应,随后免疫组化分析,原位杂交,RT-PCR,蛋白质印迹等技术用于观察葛根素对背根神经节P2X3受体mRNA和蛋白表达的抑制作用 的大鼠神经性疼痛和背根神经节和感觉神经结束于大鼠烧伤模型,通过使用全细胞膜片钳技术发现,葛根素可以显着降低P2X3受体激动剂在背侧神经元中活化的电流 神经性疼痛大鼠根神经节。 实验证明,葛根素对急性和慢性疼痛的抑制作用机制是阻断P2X3受体介导的疼痛感知信息在原发感觉神经元中的传播。 本发明提供了一种预防和治疗急性和慢性疼痛的新方法,也表明葛根素可以作为P2X3受体的拮抗剂,有利于药物在P2X3的预防和治疗中的应用 受体涉及神经系统疾病。
    • 2. 发明申请
    • APPLICATION OF PUERARIN IN THE PREPARATION OF P2X3 MEDIATED DRUGS FOR PAIN/NERVOUS SYSTEM DISEASES
    • 在制备P2X3介导的药物用于疼痛/神经系统疾病中应用PUERARIN
    • US20110152205A1
    • 2011-06-23
    • US12922245
    • 2010-06-29
    • Shangdong LiangChangshui XuYun GaoGuilin LiJiari LinShuangmei LiuHan LiuJun ZhangXin Li
    • Shangdong LiangChangshui XuYun GaoGuilin LiJiari LinShuangmei LiuHan LiuJun ZhangXin Li
    • A61K31/7034A61P25/00A61P29/00
    • A61K31/352
    • The invention relates to the new usage of puerarin in the field of pharmaceutical products, in other words, it relates to the application of puerarin in the preparation of drugs for P2X3 mediated pain/nervous system diseases. The experiment shows that puerarin can inhibit pain-related behavioral responses, subsequently immunohistochemical analysis, in situ hybridization, RT-PCR, protein blotting and other techniques were utilized to observe the inhibition of puerarin on mRNA and protein expression of P2X3 receptor in dorsal root ganglion of rats with neuropathic pain and in dorsal root ganglion and sensory nerve ending in the burn model of rats, it was found by using whole-cell patch clamp technique that puerarin can significantly reduce the electric current activated by P2X3 receptor agonist in the neuron of dorsal root ganglion of rats with neuropathic pain. The experiment proves that the mechanism for the inhibitory effects of puerarin on acute and chronic pain is to block the transmission of pain sense information that is mediated by P2X3 receptor in primary sensory neurons. The invention provides a kind of new method for the prevention and treatment on acute and chronic pain, and it also indicates that puerarin can act as a antagonist for P2X3 receptor, which will be helpful for the application of drugs in the prevention and treatment on P2X3 receptor involved nervous system diseases.
    • 本发明涉及葛根素在药物领域的新用途,换句话说,涉及葛根素在制备P2X3介导的疼痛/神经系统疾病药物中的应用。 实验表明,葛根素可以抑制疼痛相关的行为反应,随后免疫组化分析,原位杂交,RT-PCR,蛋白质印迹等技术用于观察葛根素对背根神经节P2X3受体mRNA和蛋白表达的抑制作用 的大鼠神经性疼痛和背根神经节和感觉神经结束于大鼠烧伤模型,通过使用全细胞膜片钳技术发现,葛根素可以显着降低P2X3受体激动剂在背侧神经元中活化的电流 神经性疼痛大鼠根神经节。 实验证明,葛根素对急性和慢性疼痛的抑制作用机制是阻断P2X3受体介导的疼痛感知信息在原发感觉神经元中的传播。 本发明提供了一种预防和治疗急性和慢性疼痛的新方法,也表明葛根素可以作为P2X3受体的拮抗剂,有利于药物在P2X3的预防和治疗中的应用 受体涉及神经系统疾病。
    • 9. 发明授权
    • Adaptive framework automatically prioritizing software test cases
    • 自适应框架自动优先考虑软件测试用例
    • US09489289B2
    • 2016-11-08
    • US14565220
    • 2014-12-09
    • Ziheng HuJing LiXin LiChen ZhouLonghui Chang
    • Ziheng HuJing LiXin LiChen ZhouLonghui Chang
    • G06F11/00G06F11/36
    • G06F11/3684G06F11/3688
    • An automated, self-adaptive framework prioritizes software testing in a consistent and effective manner. A metric evaluates past test execution information for assigning regression testing priority. The metric may be calculated with reference to one or more of the following factors taken in combination: requirement, coverage, history, and cost. The requirement factor considers customer-assigned priority of testing the code, complexity of implementing the code, and proneness of the code to faults. The coverage factor considers code coverage, feature coverage, and common usage rate. The history factor considers previous bug found rate, case stable rate, and priority to calculate. The cost factor considers test case execution time, and step length. A value of each factor for one test case is measured according to that test case and is not related to other test cases. The calculation result representing the metric for each test case determines a priority of the test case.
    • 自动化的自适应框架以一致和有效的方式优先考虑软件测试。 指标评估过去的测试执行信息,以分配回归测试优先级。 可以参考以下组合中的一个或多个因素来计算度量:要求,覆盖率,历史和成本。 要求因素考虑了客户分配的测试代码的优先级,实现代码的复杂性和代码的错误。 覆盖率考虑代码覆盖率,功能覆盖率和常用使用率。 历史因素考虑以前的错误发现率,病例稳定率和优先级来计算。 成本因素考虑测试用例执行时间和步长。 一个测试用例的每个因子的值根据该测试用例进行测量,与其他测试用例无关。 表示每个测试用例的度量的计算结果决定了测试用例的优先级。